Sexually Transmitted Infections (STI) in Men Who Have Sex with Men (MSM)

Göran Bratt*,1, Magnus Edlund1, Malin Cullberg2, Bo Hejdeman1, Anders Blaxhult1 and Lars E. Eriksson1,3

1Department of Clinical Science and Education, Karolinska Institute, Södersjukhuset, Unit: VenhälSAN, Stockholm, Sweden
2Department of Dermatology and Venereology, Karolinska University Hospital, Stockholm, Sweden
3Division of Nursing, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Södersjukhuset, Unit: VenhälSAN, Stockholm, Sweden

Abstract: The impact of increasingly efficient antiretroviral therapy (ART) on survival and general well-being has contributed to a “business as usual” attitude to sex among men who have sex with men (MSM). There has been a recent marked increase of sexually transmitted infections (STI) including syphilis, LGV and Hepatitis C among MSM. STIs located in the oral cavity or rectum are asymptomatic in over 80% and 50%, respectively and these sites must be seen as important reservoirs. On the other hand severe proctitis may be mistreated as inflammatory bowel disease without adequate medical history and testing. Due to the reappearance of syphilis, all genital ulcers, non-itching exanthema and severe disease symptoms (e.g. fever, fatigue, lymphadenopathy, hepa-tospleno-megaly, increased liver enzymes, neurological and ophthalmologic symptoms without other explanations) should lead to testing for syphilis. There is a marked association between STIs and HIV. Syphilis, LGV and Hepatitis C are strongly overrepresented in HIV positive MSM, while gonorrhoea, LGV and syphilis increase the HIV susceptibility. Syphilis leads to increased viral load in HIV positive. The major risk factors for Hepatitis B are number of sex partners and receptive anal intercourse. High grade Human Papilloma Virus (HPV) anal lesions can progress to cancer. There is a 30 fold increase risk for anal cancer among MSM, a risk that is doubled in HIV infection, making anal cancer one of the most common non-AIDS tumours. All MSM should be offered Hepatitis A and B vaccination and the inclusion of boys in HPV vaccination programs must be considered. The aim of this article is to describe asymptomatic and symptomatic bacterial and viral STIs of the oral cavity, penis/urethra and rectum and the sexually transmittable viral Hepatitis and HIV in MSM and to inspire the medical establishment to adhere to testing guidelines in this group. This article is built on a review of published findings, the presentation of own data on Gonorrhoea and chlamydia and our own experience in treating all STIs including HIV in MSM since 1982 at a Gay Men’s Health Clinic (VenhälSAN) at Stockholm South General Hospital, Sweden.

INTRODUCTION

This article will focus on the unique social, microbiological and medical aspects of sexually transmitted infections (STI) in men who have sex with men (MSM). This is a complex area requiring expert knowledge and frequently a multidisciplinary approach.

Firstly, despite 40 years of gay liberation, the patient may not spontaneously present himself as an MSM to the caregiver. A sexual history should always be taken with great sensitivity, with an open and unprejudiced mind. The patient should be able to speak openly and in some detail about his sexual activities, confident the care provider will be non-judgemental. If good contact is not established and communication between the doctor and patient is insufficient, medically important information might be withheld.

Secondly, many STIs affecting the mouth or the anal region are prone to be asymptomatic and persistent. Without testing for the right microbes in relevant locations, infections will be missed. To illustrate the high prevalence of STIs in asymptomatic MSM, for example, 7% of Boston MSM who reported having high risk sex in the preceding 3 months tested positive for at least one STI in the mouth, urethra or anus [1]. It is, however, notable that this study did not test for rectal and oro-pharyngeal Chlamydia trachomatis. Had such tests been included the prevalence might have been significantly higher [1]. Over half of STIs will be missed if only uro-genital testing is performed [2]. In another study of an unselected series of consecutive MSM attending Genito Urinary Medicine (GUM) clinics in the UK for sexual health screening, the prevalence of non-Lympogranuloma venerenum (LGV) Chlamydia trachomatis was 3.3% in the urethra and 7.0% in the rectum and the prevalence of LGV was 0.04% and 0.9%, respectively [3].

Thirdly, many sexual activities engaged in by MSM have implications for the STI panorama they are likely to present with. Unprotected anal intercourse is an especially effective way of transmitting pathogens like Hepatitis B and HIV.

*Address correspondence to this author at the Department of Clinical Science and Education, Karolinska Institute, Södersjukhuset, Unit: VenhälSAN, Stockholm, Sweden; Tel: +4686162500; Fax: +4686162509; E-mail: goran.bratt@sodersjukhuset.se
Another consequence of unprotected anal sex is the increased risk of human papilloma virus (HPV) induced anal cancer among MSM, a risk that is even doubled in individuals co-infected with HIV [4-6]. Oro-anal contacts facilitate the transmission of Hepatitis A, Entamoeba histolytica and other intestinal infections. Furthermore, more advanced sexual practices such as fisting and the use of sex toys seem to be risk factors for blood-borne transmitted pathogens such as Hepatitis C as well as for rectal-to-rectal STI transmission [3].

Finally, the high and increasing prevalence of long-standing and well-treated HIV infection among MSM contributes to a continuously changing epidemiology, exemplified by the increase in syphilis since 1999 [7-11], the recent reappearance of LGV (variant L2b) [12] and the increase in sexually transmitted Hepatitis C [13].

After the initial, sexually paralysing AIDS shock in the early 1980’s there was a marked decrease of STIs for over 15 years among MSM [14]. However, when the impact of protease-inhibitor based antiretroviral therapy (ART) on survival and general well-being became obvious in 1997-1998, sexual risk-taking gradually increased among MSM. The emergence of increasingly efficient ART combinations with improving long-term safety and simplicity resulting in an undetectable viral load in the overwhelming majority of treated subjects together with a media-silence regarding HIV have resulted in a “business as usual” attitude to sex. The optimally treated HIV patient’s sense of wellbeing and their belief of being less infectious have also had an impact. However, the statement that patients on effective ART who are free of any other STI cannot transmit HIV through sex has been questioned [15]. Other developments facilitating the spread of all STIs include the eroticisation of “bare-backing” and the exchange of sperm among many HIV positive MSM, encouraged by numerous internet sites aiming at so-called “sero-sorting” and “poz-parties”. Obviously, less condom use and an increased number of sexual encounters increase the transmission of other STIs [16].

The aim of this article is to focus on some aspects of asymptomatic as well as symptomatic bacterial and viral STIs of the oral cavity, penis/urethra and rectum, the sexually transmissible viral Hepatitis and HIV in MSM and to discuss testing guidelines. This article is built on a review of published findings, own original data regarding Gonorrhoea and chlamydia and our own experience in treating MSM with all forms of STIs including HIV since 1982 at a Gay Men’s Health Clinic (Venhälsan) at Stockholm South General Hospital, Sweden. Venhälsan started in 1982 as a response to the international reports of AIDS and other STIs among MSM with the ambition to reach as many MSM as possible and offer STI-testing and counselling, which since 1985 also included HIV [17]. Venhälsan cares today for 1000 HIV positive patients, of whom 80% are MSM and have approximately 7000 annual visits for STI/HIV testing.

**MATERIALS & METHODS**

All patients presenting at Venhälsan are offered oropharyngeal, urethral/urine and anorectal testing for Gonorrhoea and chlamydia. We have revised all the files of patients with positive Gonorrhoea and chlamydia results during 2007 and 2008. All patients are MSM.

In addition a review of the literature on STIs in MSM has been performed and our results are discussed in relation to American and European published reports.

**Results from Venhälsan**

Two hundred and thirty six individuals tested positive for Gonorrhoea, 17% had a known HIV-infection and in 5% HIV was diagnosed at the time of Gonorrhoea (Table 1a). The median age was 31 years. Symptoms were noted only in 32%, 13% and 96% of the patients with ano-rectal, oropharyngeal and urethral Gonorrhoea, respectively (Table 1b). Signs/symptoms of proctitis were not more common in HIV-positive as compared to HIV-negative MSM (Table 1c). Newly diagnosed HIV-infection occurred in 8% and 3% of the patients with ano-rectal and urethral Gonorrhoea, respectively, but not in any of the patients with oropharyngeal Gonorrhoea (Table 1b). Only 4% and 15% of patients with ano-rectal Gonorrhoea with and without signs/symptoms of proctitis, respectively, were positive in the urethral Gonorrhoea culture (Table 1c).

Four hundred and thirty one tested positive for chlamydia, 24% had a known HIV-infection and in 4% HIV was diagnosed at the time of chlamydia (Table 2a). The median age was 34 years. Symptoms were noted only in 34%, 16% and 51% of the patients with ano-rectal, oropharyngeal and urine chlamydia, respectively (Table 2b). Of the patients with rectal chlamydia 17(6%) had anal condylomata. Signs/symptoms of proctitis were more common in HIV-positive as compared to HIV-negative MSM (43/74 (58%) vs 51/199 (26%); p<0,001 (Fisher’s exact test). Of HIV-positive and HIV-negative patients with signs/symptoms of proctitis and positive Chlamydia test 30% and 4%, respectively had LGV (Table 2c). Newly diagnosed HIV-infection occurred in 5%, 2% and 2% of the patients with ano-rectal, oropharyngeal and urine chlamydia, respectively (Table 2b). Only 6% and 14% of patients with ano-rectal chlamydia with and without signs/symptoms of proctitis, respectively, were positive for chlamydia in the urine (Table 2c). Contact tracing was the most common reason for the visit in patients with oro-pharyngeal and ano-rectal Gonorrhoea and chlamydia (Tables 1b, 1c, 2b and 2c).

**Localized Asymptomatic STIs**

Gonorrhoea has been shown to be transmitted bi-directionally through oro-penile sex [18] and the same seems true for chlamydia [19]. Gonorrhoea and chlamydia usually cause no symptoms in the oral cavity and oro-pharyngeal symptoms are not predictive of Gonorrhoea/chlamydia, making this site an ideal and frequently overlooked STI reservoir. In one study only 18.2% and 16.7% of the cases with oro-pharyngeal Gonorrhoea and chlamydia, respectively, would have been identified on symptom-lead testing [20]. We found 87% and 84% of MSM with oro-pharyngeal Gonorrhoea and chlamydia, respectively, to be asymptomatic and 51% and 43% of the patients with positive oro-pharyngeal tests, respectively, were only positive in the mouth (Tables 1b and 2b). Syphilitic ulcers are probably also often overlooked in the oral and ano-rectal sites, especially as they can be painless. In our practice only 9% of
primary syphilitic lesions are located orally and 23% ano-
rectally [21]. Overall ano-rectal symptoms do not differ
between men with and without ano-rectal gonorrhoea/non-
LGV chlamydia [22]. However, heavy anal discharge and
pain was associated to ano-rectal Gonorrhoea in one study
[22]. Patients with ano-rectal Gonorrhoea/non-LGV
chlamydia are more likely to be asymptomatic than those
with urethral infections [20, 23, 24]. Rectal Gonorrhoea
is reported to be asymptomatic in 50-68% and rectal non-LGV
chlamydia in 52-86% [3, 7, 19, 24-26]. Tables 1b and 2b.
We found 55% of MSM with rectal Gonorrhoea to have
normal anoscopy (Table 1b). Most oro-pharyngeal and ano-
rectal Gonorrhoea and chlamydia would go undiagnosed and
untreated without testing in these sites [2, 26, 27], for
example we found that 67% and 82%, respectively, of
the patients with positive ano-rectal samples were positive only
in this site (Tabled 1b and 2b). Routine testing for oro-
pharyngeal and asymptomatic ano-rectal STIs in MSM in
different settings has revealed a Gonorrhoea prevalence of
1.7-9.2% and 5.0-6.9%, respectively, and a chlamydia
prevalence of 1.2-1.7% and 4.7-8.8%, respectively, in [1, 7, 18-
20, 28, 29]. Urethral chlamydia, now common in MSM with
a prevalence of 6% in the US [30], is asymptomatic in 42-
50% of the cases [3] (Table 2b). A positive urine/urethral
chlamydia test is found in only 8-15% of MSM with
asymptomatic rectal chlamydia [26] (Table 2c).

We found an overrepresentation of oro-pharyngeal
chlamydia and coexisting oro-pharyngeal and rectal
chlamydia among MSM being contact traced/partner notified
for chlamydia, high lightening the importance of
asymptomatic oral and rectal chlamydia reservoirs [19].
Rectal Gonorrhoea and chlamydia often co-exist, 6.5-13.4%
of patients with rectal chlamydia also had Gonorrhoea [19,
26] (Table 2b), while 17.8% of patients with rectal
Gonorrhoea also had chlamydia (Table 1b).

Although LGV often presents with severe proctitis,
asymptomatic ano-rectal LGV does occur, the reported
frequency varies considerably from 0% in Canada, 5-17% in
London and 12-13% in Stockholm to the majority of cases in
the Netherlands [3, 19, 26, 28, 31, 32] (Table 2e).

Localized Symptomatic STIs

Oro-Pharyngeal

Of patients with oro-pharyngeal Gonorrhoea and chlamydia,
10-13% and 16% reported pharyngitis and/or tonsillitis [33]
(Table 1b and 2b). Oro-pharyngeal Gonorrhoea is more
difficult to eradicate than ano-genital with approximately 9-10%
treatment failures on single dose cefixime or ceftriaxone – a
further contributing factor to a reservoir for continuing
transmission [27, 34]. Treatment with single dose cefixime in
combination with 1 g azithromycin has improved efficacy and
been reported, in some studies with small numbers of patients,
to result in 100% negative control cultures [34].

Cervical lymphadenopathy related to oro-pharyngeal LGV
has been reported and might become an increasing problem
[35].

Penile

Urethral Gonorrhoea is usually symptomatic and is rare
in asymptomatic men [1, 20] (Table 1b). Symptoms of
gonococcal urethritis include various degrees of urinal
pain/itching and mucopurulent discharge. Urethral
chlamydia, in contrast, only causes symptoms in 32-69% [3,
19, 26] (Table 2b). The symptoms of chlamydia infection are
usually mild with a watery discharge. Chlamydial/gonoco-
ccal epididymitis or prostatitis are rarely seen in our patient
cohort, possibly because such patients are acutely ill and
tend to seek the emergency ward rather than an STI clinic.

LGV may cause genital ulcers and urethral infection with
inguinal adenopathy and should always, together with
Herpes simplex and primary syphilis, be a differential
diagnosis when evaluating genital ulcers [36]. Oral sex may
lead to oro-penile transmission of various respiratory
pathogens such as Moraxella, Streptococci spp and
Haemophilus parainfluenzae [37, 38] and unprotected anal
sex might cause E. coli urethritis. Although not extensively
studied, urethritis caused by Mycoplasma genitalium, does
not seem to be overrepresented in MSM, probably since it is
not transmitted by oral sex [39].

Ano-Rectal

Symptoms of proctitis are: pain, purulent and/or
haemorrhagic discharge, tenesmus, irritation, itching,
diarrhoea and/or constipation [40]. It is not uncommon that
patients with a severely sexually acquired rectal infection like
LGV have symptoms suggestive of Crohn’s disease [41].
They may initially present at a gastroenterology or colorectal
department and receive treatment for inflammatory bowel
disease [42, 43] (Table 1b). Even in the pre-AIDS 1970’s the
frequency of ano-rectal disease in MSM received attention
and was given the misleading term ‘gay Bowel Syndrome”
[44]. This represented a mixture of intestinal infections like
amoebiasis, shigellosis, proctologic problems like peri-rectal
abscesses, fissures, haemorrhoids, fistulas, rectal trauma,
itching and dyspareunia and STIs. Infectious proctitis is
more common than non-infectious with common causes
including Gonorrhoea, chlamydia, syphilis and Herpes
simplex [40]. In a series of 125 MSM with symptomatic
proctitis in the Netherlands 26% had LGV, 18% Gonorrhoea
and 24% non-LGV chlamydia [31]. For details about clinical
features, diagnostic tests and management of proctitis the
reader is referred to the 2007 updated European Guidelines
(IUSTI/WHO) on the management of proctitis, proctocolites
and enteritis caused by sexually transmitted pathogens [45].
It is recommended to start treatment at least covering
Gonorrhoea, LGV and Herpes in severe cases [40].

Ano-Rectal Herpes Simplex

Acute Herpes simplex proctitis may cause fever, and in
addition to the symptoms described above difficulty in
urinating, sacral paresthesia, inguinal lymphadenopathy,
severe ano-rectal pain, and peri- and intra-anal ulcerations,
especially during the first episode of HSV-2. HSV-2 was
detected in 23% of MSM with proctitis in one early study
[46].

Ano-Rectal Mycoplasma Genitalium

There are only a few studies of ano-rectal Mycoplasma
genitalium, but 5.4% of rectal specimens in a cross-sectional
pilot study in an STI clinic in San Fransisco were positive
and there was a weak association to rectal symptoms and
proctitis [47]. Interestingly, in the multivariate analysis only
positive HIV status was associated with Mycoplasma genitalium infection [47].

Ano-Rectal Syphilis

It is important to remember that syphilis may cause severe very painful ulcerative proctitis, sometimes with an anorectal mass.

Ano-Rectal Gonorrhoea

Symptoms of proctitis were significantly more common in rectal Gonorrhoea than in isolated rectal non-LGV chlamydia infection in one study [48]. In our cohort of 100 patients with rectal Gonorrhoea, 32% presented with ano-rectal symptoms and 45% had an anoscopy verified proctitis (Table 1b). Two patients had anal abscesses with growth of gonococci and one patient had been treated for inflammatory proctitis at the gastroenterology department prior the correct diagnosis being made (Table 1b).

Ano-Rectal Non-LGV Chlamydia and LGV

Both non-LGV chlamydia and LGV can cause severe proctitis, however, non-LGV infections are usually milder [41, 43]. As early as 1981-83 LGV was associated with severe proctitis [41], one case presenting with massive rectal bleeding [42]. Although urethral/penile LGV presenting with ulcers has been reported, severe painful ulcerative purulent proctitis with rectal discharge, urge to defecate, tenesmus and the passage of blood are frequently the dominating symptoms of LGV [49]. Untreated chronic LGV may lead to abscesses that may rupture, severe perianal fistulas, genital elephantiasis, strictures and fibroses and may resemble Crohn’s disease, although the appearance is non-specific [49]. The local lymph nodes are involved with pain, swelling, necrosis and perforation [12, 49]. Since the recognition of the ongoing outbreak of LGV among MSM in Rotterdam, Holland [50], infections have been reported from many parts of Europe, North America and Australia [12, 31, 49] and LGV has become endemic among MSM in some areas of the UK [3]. From our experiences 14-16% of patients with symptomatic rectal chlamydia had LGV, a figure increasing to 30% in the case of HIV-positive patients [19] (Table 2c). The majority of LGV patients in the current outbreak are HIV positive, and often have other STIs at the LGV diagnosis [12, 19]. A high proportion of HIV negative MSM with LGV become HIV positive soon after the LGV diagnosis [51]. In a Dutch study comparing proctitis of different causes, LGV patients were older, had more often a history of syphilis and Hepatitis C and 78% were HIV-positive [31]. The use of sex toys, enemas, having sex at parties and sex with HIV positive partners came out as significant LGV risk factors in multiple logistic regression [31]. In a case-control study of symptomatic rectal infections

### Table 1a. All Gonorrhoea Diagnosed at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%)

<table>
<thead>
<tr>
<th>n</th>
<th>Positive at More Than One Site n (%)</th>
<th>Age (Years: Median and Range)</th>
<th>Also Diagnosed with Chlamydia n (%)</th>
<th>Known HIV Infection n (%)</th>
<th>Newly Diagnosed HIV Infection n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>236</td>
<td>47 (20)</td>
<td>31 (17-67)</td>
<td>42 (18)</td>
<td>39 (17)</td>
<td>11 (5)</td>
</tr>
</tbody>
</table>

### Table 1b. Gonorrhoea in Different Sites Diagnosed at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%)

<table>
<thead>
<tr>
<th>Site of Positive Gonorrhoea Culture</th>
<th>n</th>
<th>Only One Site n (%)</th>
<th>Testing Due to Contact Tracing n (%)</th>
<th>Symptoms in the Positive Site n (%)</th>
<th>Known HIV Infection n (%)</th>
<th>Newly Diagnosed HIV Infection n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharyngeal</td>
<td>87</td>
<td>44 (51)</td>
<td>29 (33)</td>
<td>11 (13)</td>
<td>6 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Urethral</td>
<td>103</td>
<td>79 (77)</td>
<td>5 (5)</td>
<td>99 (96)</td>
<td>20 (20)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Anorectal</td>
<td>100</td>
<td>67 (67)</td>
<td>43 (43)</td>
<td>32 (32)*</td>
<td>19 (19)</td>
<td>8 (8)</td>
</tr>
</tbody>
</table>

* 45 (45%) had pathological anoscopy. Two patients had rectal abscesses with growth of gonococci, two had rectal fissures and one was admitted to the gastroenterology clinic and received treatment for inflammatory bowel disease.

### Table 1c. Ano-Rectal Gonorrhoea at Venhälsan, Stockholm 2007-2008. Data are Given as n and (%)

<table>
<thead>
<tr>
<th>Positive Ano-Rectal Gonorrhoea (n=100)</th>
<th>n (%)</th>
<th>Also Positive in Urethra n (%)</th>
<th>Testing Due to Contact Tracing n (%)</th>
<th>Ano-Rectal Chlamydia n (%)</th>
<th>Known HIV Infection n (%)</th>
<th>Newly Diagnosed HIV Infection n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sign/symptom of proctitis; HIV-positive and negative</td>
<td>45 (45)</td>
<td>2 (4)</td>
<td>9 (20)</td>
<td>9 (20)</td>
<td>9 (20)</td>
<td>4 (9)</td>
</tr>
<tr>
<td>Sign/symptom of proctitis; HIV-positive</td>
<td>13 (13)</td>
<td>0 (0)</td>
<td>2 (15)</td>
<td>4 (31)</td>
<td>9 (69)</td>
<td>4 (31)</td>
</tr>
<tr>
<td>Sign/symptom of proctitis; HIV-negative</td>
<td>32 (32)</td>
<td>2 (6)</td>
<td>7 (22)</td>
<td>5 (16)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No sign/symptom of proctitis; HIV-positive and negative</td>
<td>55 (55)</td>
<td>8 (15)</td>
<td>34 (62)</td>
<td>10 (18)</td>
<td>10 (18)</td>
<td>4 (7)</td>
</tr>
</tbody>
</table>
in London LGV was associated with rectal discharge, higher age, fisting, HIV infection and less protected anal intercourse [43]. LGV treatment consists of doxycycline 100 mg twice daily for 21 days and should be initiated on suspicion in chlamydia positive proctitis, especially in HIV-positive patients, since confirmation might be delayed [40, 43].

### Syphilis

Untreated syphilis is highly contagious during the first 2 years (early syphilis). The main route of transmission is unprotected oral and anal intercourse. Since unprotected oral sex, considered less risky regarding HIV transmission, is widely practised among both HIV negative and positive MSM, it has been considered the most important manner of transmission [9, 52]. High numbers of anonymous contacts and delays in diagnosis lead to an increased transmission rate and great difficulties in contact tracing [9]. During the 1980’s and early 90’s there was a marked decrease of syphilis in Western Europe [53, 54]. Experience of syphilis infection both among doctors and MSM was lacking at the beginning of the current outbreaks. All genital ulcers, non-itching exanthera and severe disease symptoms (e.g. fever, fatigue, lymphadenopathy, hepatosplenomegaly, increased liver enzymes, neurological and ophthalmological symptoms) without an obvious explanation should lead to testing for syphilis, especially in MSM, regardless of HIV status. During the last 10 years there have been numerous outbreaks of syphilis among MSM [7], starting in Dublin, Oslo and cities in the UK, to be followed in all major cities in Europe and North America, as well as other parts of the world [7, 9, 10, 55, 56]. There is a strong association between syphilis and other STIs, especially HIV [7-11]. The HIV prevalence among MSM diagnosed with syphilis in Europe is reported between 14-59% [7, 21]. HIV infection seems to increase the susceptibility for syphilis and co-infection with syphilis was the greatest risk factor for a new HIV infection in one study [57]. Between 2-5% are diagnosed with syphilis and HIV at the same time [7, 21]. We have found that 10% of HIV negative men with syphilis 1999-2009 have become HIV infected after their syphilis infection and that 25% of newly diagnosed HIV positive men have had syphilis [21]. Untreated syphilis in HIV positive subjects leads to increased viral load and decreased CD4 levels [58] and is reported to progress more rapidly with increased risk for early cerebral/ocular involvement, especially if the CD4 count is low and the HIV infection is untreated [59]. There is an increased risk to infect sex partners with HIV [11, 58, 60]. In 10-13% of patients gonorrhoea and/or chlamydia is also diagnosed at the same time as syphilis [9, 21] and of our patients with Gonorrhoea and chlamydia 4 and 3%, respectively, were simultaneously diagnosed with syphilis (data not shown). Staging of the syphilis infection in our cohort showed 52% to have primary syphilis, usually with a
During the last two decades the proportion of newly HIV diagnosed MSM at our clinic with positive HBsAg and positive anti-HBc has been 3% and 38%, respectively (own unpublished data). Chronic HBV infection is related to 60-90% of all hepatocellular carcinomas in adults, a preventable disease as first evidenced by the universal vaccination program in Taiwan [70]. Although an effective recombinant vaccine has been in existence for 25 years, vaccination rates among MSM are still low [71], although rising [48]. Routine HBV immunization with 3 injections, which in most countries has been introduced as universal childhood vaccination, is also recommended for all MSM and for persons evaluated or treated for STIs [63]. Modern antiviral therapy in individuals who develop chronic infection and do not clear the virus themselves include tenofovir, which is highly effective in promoting a durable and sustained suppression of the virus, increasing survival and quality of life and hopefully preventing end stage liver disease and hepatocellular cancer. Such treatment aims at undetectable HBV DNA and is comparable to HIV-treatment [72].

Hepatitis A

Hepatitis A (HAV) is easily transmitted through sexual practices involving fecal-oral exposure [63]. Although HAV never becomes chronic, HAV more often causes significant clinical disease than hepatitis B. There have been several outbreaks of HAV in MSM e.g. in 1979-1980 in Stockholm [64]. In 1982, prior to any HAV vaccination, we found 26% of the attending MSM to be anti-HAV positive [17]. Although effective vaccination with formalin killed HAV (preferably administered as two doses with 6 months interval) has been generally available at a low cost for many years, only half of MSM in UK are anti-HAV IgG positive [65]. The relative failure in offering MSM HAV-vaccination has resulted in continuing regular HAV outbreaks, e.g. in Copenhagen 2004 where casual sauna sex appeared to be a risk factor [66]. As the general immunity to HAV decreases in the western community, all MSM not living in monogamous relationships, are advised to undergo HAV immunization [63].

Hepatitis B

In industrialized countries most cases of hepatitis B virus (HBV) infection are acquired through sexual intercourse or through needle sharing by intravenous drug users (IVDU) [63]. The major risk factors for HBV infection in MSM include receptive anal intercourse and the number of sex partners [67]. The initial epidemiological matching of HBV and AIDS generated a hypothesis of HBV being a cofactor for AIDS [68]. HBV infection is prevalent and most often asymptomatic among MSM but may lead to significant morbidity and death. The prevalence of positive HBV surface antigen (HBsAg) and antibodies to the HBV core antigen (anti-HBc) has been found to be 1-6% and 12-68%, respectively, in MSM in various materials during the last 30 years [17, 48, 63, 69]. During the last two decades the proportion of newly HIV diagnosed MSM at our clinical with positive HBsAg and positive anti-HBc has been 3% and 38%, respectively (own unpublished data). Chronic HBV infection is related to 60-90% of all hepatocellular carcinomas in adults, a preventable disease as first evidenced by the universal vaccination program in Taiwan [70]. Although an effective recombinant vaccine has been in existence for 25 years, vaccination rates among MSM are still low [71], although rising [48]. Routine HBV immunization with 3 injections, which in most countries has been introduced as universal childhood vaccination, is also recommended for all MSM and for persons evaluated or treated for STIs [63]. Modern antiviral therapy in individuals who develop chronic infection and do not clear the virus themselves include tenofovir, which is highly effective in promoting a durable and sustained suppression of the virus, increasing survival and quality of life and hopefully preventing end stage liver disease and hepatocellular cancer. Such treatment aims at undetectable HBV DNA and is comparable to HIV-treatment [72].

Hepatitis C

Although needle sharing among IVDU is considered the main way of transmission, a proportion of HCV infected individuals are not IVDU, many of whom may have been sexually infected. HCV infection causes no symptoms during the first couple of decades; the only signs being raised liver enzymes. Since 2000 there has been a marked rise in hepatitis C (HCV) infection in HIV-positive MSM in different countries with circulating clusters of limited genotypes (1a, 4d, 3a, 1b and 2b/c), suggesting an “international transmission network” [73]. Sexual spread of HCV seems to coincide with syphilis and LGV in HIV positive MSM [74]. In France, for example, the prevalence of HCV among HIV-positive MSM was 3.1% in 2004 [75] and in the UK an annual incidence rise of 20% among HIV positive MSM was found between 2002 and 2006 [76], whilst the prevalence in HIV-positive MSM in Amsterdam increased from 15% to 21% between 2007 and 2008 [13]. It is important to be aware of the persistent high-risk behaviour in a subgroup of HIV positive MSM and perform intense counselling as well as screening for STIs including HCV in this group. Finding all HCV infected individuals is crucial, since today’s and tomorrow’s treatment options are rapidly making HCV a potentially curable disease [77]. We have neither ourselves nor in the literature found an overrepresentation of HCV in HIV negative MSM. Although this could change rapidly, for the moment there are no data indicating spread of HCV to HIV negative MSM through sex [76].

Human Papilloma Virus (HPV)

HPV is easily transmittable through all intimate contacts. International studies show a high prevalence of HPV in MSM in general and in HIV positive MSM in particular. The basal cell of the anal epithelium is highly susceptible to HPV infection. Approximately 15 types of HPV are classified as "high risk" (e.g. HPV 16 and 18) due to their association with cervical cancer, other ano-genital cancers, and tonsillar squamous cell carcinoma [78, 79]. In addition, there are also a number of "low risk" HPV types e.g. HPV 6 and 11 related to condylomata acuminata (genital warts). Despite the high
prevalence of persistent HPV infection, the progression to pre-cancerous dysplasia tends to be relatively rare and slow, thus allowing for intervention over long time [78]. In a sample of MSM 85% had “low-risk” and 77% “high-risk” anal HPV, with a mean of 4.2 concurrent HPV types in HIV negative and 7.1 in HIV positive men. “High-risk” HPVs were associated with anal condyloma in HIV negative and anal bleeding in HIV positive men [80]. In another sample from San Francisco, 34% of the HIV negative MSM and 72% of the HIV positive MSM carried “high-risk” HPV [81]. Furthermore, a longitudinal Canadian study found anal HPV in almost 98% of HIV-positive MSM, with a mean of five types simultaneously, most frequently HPV 16 (38%) and HPV 6 (35%) with the lowest clearance rate seen for HPV 16 [82].

**Anal Cancer**

Cervical and anal cancers are similar in so far as they occur in the transition zone between columnar and squamous epithelium. There is increasing evidence that high-grade HPV-related anal lesions can progress to cancer over time [83]. A recent review comprising 37 international studies found an HPV 16/18 prevalence of 72% in invasive anal cancer, 69% in high-grade and 27% in low-grade anal squamous intraepithelial lesions [84]. Cross-sectional studies have found prevalence’s of anal cancer precursor changes of 5-35% in HIV negative and 15-59% in HIV positive MSM [81, 85, 86]. A French study found HPV related lesions in 37% of HIV infected MSM, of which over half hade histologically verified dysplasia [87]. Risk factors for squamous intraepithelial lesions in HIV negative and anal cancer in HIV positive MSM include older age at first receptive anal intercourse, high frequency of unprotected receptive anal intercourse, use of injection drugs, anal HPV infection and higher number of concurrent HPV types [85, 87]. Other contributing factors include low CD4 cell count, and cigarette smoking [83, 88]. The incidence of anal cancer is increasing and is particularly high in MSM with the highest incidence in HIV infected MSM [78]. The relative risk for anal cancer in HPV infected individuals as compared to the general population is 31.2 in MSM and up to 60 in HIV positive MSM and actually both are higher than for cervical cancer [4-6]. HIV infected patients are at higher risk of viral persistence, multiple HPV genotypes (mainly HPV-16), squamous intraepithelial cancer precursor lesions and progress to invasive cancers [89]. The longer survival of HIV-positive subjects allows progression of HPV preneoplastic disease to cancer, whereas immunologic improvement does not affect the incidence of HPV-infections, which is more related to risk behaviour. Anal cancer is one of the most common non-AIDS defining tumours in HIV positive MSM and is increasing despite effective ART [83]. In our own clinical cohort of 202 HIV infected patients, of whom 188 are MSM who started ART in 1996, eight (4%) have developed anal cancer to date (Bratt, Eriksson et al. unpublished data).

**HPV-Vaccines**

In 2006, new vaccines against HPV 16 and 18 with or without effect also against two “low-risk” HPVs were licensed in the US and Europe. The vaccine’s preventive effect can only be fully achieved if given prior to HPV exposure and if followed up with booster doses. Recently, vaccination programs for girls have been implemented in several European countries. However, the models that underlie the implementation of those vaccination programs do not take into account non-cervical HPV related cancers and do not consider other sexual behaviour than conventional heterosexual intercourse [90]. A review and a meta-analysis suggest that HPV vaccination could prevent 80% of anal carcinoma if both sexes were included in vaccination programs [84, 91]. Although sparsely investi-gated among MSM, studies indicate lack of knowledge about HPV and its relation to condyloma and anal cancer in general [92, 93] and about HPV vaccines in particular [94]. We feel that there is an urgent need to investigate the cancer preventive effect of HPV vaccines in MSM and the feasibility of including both men and women in vaccine programs.

**HIV**

STIs are markers for high risk sex through which HIV can be transmitted. STIs also facilitate transmission and acquisition of HIV through several direct biological mechanisms, including boosting genital HIV shedding, increasing recruitment of “ready to be infected” lymphocytes and macrophages and disrupting the mucosal barrier [57, 60]. Gonorrhoea, syphilis and to a lesser extent chlamydia are associated with higher amounts of HIV in genital secretions in co-infected subjects [95]. To increase the knowledge about actual risk factors for becoming HIV positive detailed studies of the recently HIV infected MSM are crucial. Recently acquired HIV is associated with having had an STI the last years and often having a concurrent STI, especially syphilis and rectal and urethral Gonorrhoea [96-98]. In one study 23% of newly HIV diagnosed MSM were concomitantly co-infected with another STI, with syphilis as the greatest risk (OR=11.1 (95% CI:7.7-15.8)) [57]. In our own clinic this figure is 29%, while 41% had had an STI during the last 2 years [99]. Gonorrhoea and chlamydia were found in 26% and 19%, respectively, among newly HIV-diagnosed MSM in San Francisco [100]. Concurrent chlamydia, Gonorrhoea and syphilis were significant predictors of new HIV in four US metropolitan areas 2002-2006 [101]. Ano-rectal Gonorrhoea is an independent risk factor for HIV seroconversion [102] and high rates of new HIV infections have been observed after ano-rectal Gonorrhoea [98]. Also chlamydia has been associated to HIV infection [103]. HIV positive MSM have a greater STI burden, especially urethral Gonorrhoea and syphilis and are more often asymptomatic as compared to HIV negative MSM. A Californian study found a baseline prevalence of STIs of 14% and an annual incidence of 21 cases per 100 person years in asymptomatic HIV positive MSM [104].

**DISCUSSION**

Prompt testing, counselling, diagnosing and treatment of STIs are extremely important in a comprehensive HIV prevention strategy among MSM [60]. A visit at an STI clinic is also an excellent opportunity for the nurse or physician to discuss safer sex practices and to update the client of the current local STI situation and the importance of STIs, especially rectal infections and syphilis for HIV transmission [21, 98].

HIV testing/counselling (traditional or rapid test) should always be suggested since it is crucial that HIV infected
individuals become aware of their infection as soon as possible after being infected. We have had excellent experience with a low-threshold rapid HIV testing program combined with a single structured counselling session. STIs are important cofactors for HIV transmission and markers of unprotected sex. A sexual history obtained in the clinical setting is often unreliable, and a standard testing procedure has many advantages over symptom-driven testing [104]. This is regardless of whether the patient seeks for localized symptoms or a general check-up. Since co-infections are common, a standardized testing regime including all infections at all locations is necessary. It is crucial to encourage all nurses and physicians engaged in the health care of MSM to follow guidelines for STI screening [104].

Gonorrhoea and chlamydia testing (with the methods as recommended by the local lab) should be carried out from the oral cavity (tonsillar and pharyngeal, respectively), the urethra/urine and the anal canal. Since lubricants have a mild bacteriostatic effect, it is important to use a technique minimizing lubrication prior to testing, either blindly or under direct vision through the anoscope [40]. Rectal examination with anal inspection and digital palpation is an excellent and simple method to detect warts, ulcers and tumours. Positive rectal chlamydia samples should be sent to a specialist lab for LGV sequencing. Blood should be tested for syphilis, Hepatitis A, B (in non-immune subjects) and C and HIV. Patients that are contact traced and/or partner notified for one infection should always be tested also for the other infections since different STIs very often co-occur in this group. Hepatitis A and B vaccination should always be suggested in non-immune subjects. Annual routine STI screening including HIV testing is recommended for all sexually active MSM [105]. Screening every 3-6 months has been advised for those at highest risk i.e. men with multiple partners, those using alcohol and drugs in conjunction with sex and those travelling to high risk cities for sex encounters. Sexually active HIV-positive MSM should have an STI screening including rectal palpation and anoscopy at least annually. We think that there is a strong need for specialist departments aimed at MSM where patients can feel secure, with a team that is up to date on the continuously changing STI epidemic situation. In such an environment important data can be collected and research stimulated.

REFERENCES

[22] Lister NA, Chaves NJ, Phang CW, Smith A, Fairley CK. Clinical significance of questionnaire-elicited or clinically reported anorectal symptoms for rectal Neisseria gonorrhoeae and Chlamydia trachomatis amongst men who have sex with men. Sex Health 2008; 5: 77-82.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Garnett GP, Kim JJ, French K, Goldie SJ. Modelling the impact of
Orlando G, Mayeaux EJ, Jr., et al. Advances in prevention of
cervical cancer and other human papillomavirus-related diseases.
papillomavirus (HPV) positive tonsillar carcinoma in Stockholm,
Sweden: an epidemic of viral-induced carcinoma? Int J Cancer
papillomavirus genotype diversity and co-infection in a
community-based sample of homosexual men. Sex Transm Infect
2009 (in press).
Chin-Hong PV, Berry JM, Cheng SC, et al. Comparison of patient-
and clinician-collected anal cytology samples to screen for human
papillomavirus-associated anal intraepithelial neoplasia in men who
de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence,
clearance, and incidence of anal human papillomavirus infection in
199: 965-73.
Kreuter A, Wieland U. Human papillomavirus-associated diseases
in HIV-infected men who have sex with men. Curr Opin Infect Dis
Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus
Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-related
prevalence of anal cancer precursors in homosexual men: the
Kreuter A, Brockmeyer NH, Weissenborn SJ, et al. Penile
intraepithelial neoplasia is frequent in HIV-positive men with anal
squamous intraepithelial lesions and condyloma in HIV-infected
heterosexual men, homosexual men and women: prevalence and
D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of
anal cancer in the multicenter AIDS cohort study. J Acquir Immune
genotypes and anal-related lesions among HIV-1-infected men in
Garnett GP, Kim JJ, Frenck K, Goldie SJ. Modelling the impact of
HPV vaccines on cervical cancer and screening programmes.
Vaccine 2006; 24(Suppl 3): S3178-86.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human
papillomavirus in carcinoma and intraepithelial neoplasia of the
vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:
1626-36.
Pitts MK, Fox C, Willis J, Anderson J. What do gay men know
about human papillomavirus? Australian gay men's knowledge and
experience of anal cancer screening and human papillomavirus.
Tider DS, Parsons JT, Bimbi DS. Knowledge of human
papillomavirus and effects on sexual behaviour of gay/bisexual
Simatherai D, Brashaw CS, Fairley CK, Bush M, Heley S, Chen
MY. What men who have sex with men think about the human
Cohen MS, Hoffman IF, Royce RA, et al. Reduction of
concentration of HIV-1 in semen after treatment of urethritis:
of persons with recently acquired HIV infection: application of the
serologic testing algorithm for recent HIV seroconversion in 10 US
Garvey LJ, Roberts C, Smith A. Confirmed new HIV diagnoses in
men who have sex with men after episodes of rectal gonorrhoea. Int
Acquir Immune Defic Syndr 2009; 20: 144.
Bratt G, Hejdeman B. Sexually transmitted infections increase
the risk of HIV: a survey among men who have sex with men shows
a strong connection. Lakartidningen 2006; 103: 1438-9.
Scott KC, Philip S, Ahrens K, Kent CK, Klausner JD. High
prevalence of gonococcal and chlamydial infection in men who
have sex with men with newly diagnosed HIV infection: an
opportunity for same-day presumptive treatment. J Acquir Immune
Helms DJ, Weinstock HS, Mahle KC, et al. HIV testing frequency
among men who have sex with men attending sexually transmitted
disease clinics: implications for HIV prevention and surveillance. J
Crab RJ, Meddings DR, Strathdee SA, et al. Rectal gonorrhoea as
an independent risk factor for HIV infection in a cohort of
Joyce AG, Thayagarajan SP, Reddy EV, Venkatesan C, Ganapathy
M. Genital chlamydial infection in STD patients: its relation to
Rieg G, Lewis RJ, Miller LG, Witt MD, Guerrero M, Daar ES. Asymptomatic sexually transmitted infections in HIV-infected men
who have sex with men: prevalence, incidence, predictors, and
Branson BM, Handsfield HH, Lampe MA, et al. Revised
recommendations for HIV testing of adults, adolescents, and
pregnant women in health-care settings. MMWR Recomm Rep

Received: August 10, 2009
Revised: September 22, 2009
Accepted: September 28, 2009

© Bratt et al.; Licensee Bentham Open.
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.